PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Experimental treatment developed at UCLA eradicates acute leukemia in mice

2014-02-27
(Press-News.org) A diverse team of scientists from UCLA's Jonsson Comprehensive Cancer Center has developed an experimental treatment that eradicates an acute type of leukemia in mice without any detectable toxic side effects. The drug works by blocking two important metabolic pathways that the leukemia cells need to grow and spread.

The study, led by Dr. Caius Radu, an associate professor of molecular and medical pharmacology at UCLA, and Dr. David Nathanson, an assistant professor of molecular and medical pharmacology, was published in the Journal of Experimental Medicine.

Elements of metabolism called biosynthetic pathways allow cells to synthesize chemicals, called nucleotides, that they need to survive. When these nucleotide pathways are blocked by drug molecules, cancer cell growth can be halted, which can trigger cell death.

Radu, Nathanson and their colleagues found that an important nucleotide called deoxycytidine triphosphate (dCTP) is produced by two pathways, the de novo pathway and the nucleoside salvage pathway.

When an existing drug was given that blocks the de novo pathway in a leukemia cell, the dCTP nucleotide was still produced by the nucleoside salvage pathway, and the leukemia cell survived.

To counter this switch to the alternative pathway, the researchers also administered a small-molecule drug called DI-39 — developed exclusively at UCLA — which blocks the nucleoside salvage pathway. When both of the drugs are given, both pathways are blocked, the leukemia cells cannot produce dCTP nucleotides and the cells die.

In the study, the experimental treatment was given to mice with acute lymphoblastic leukemia, a deadly blood cancer. The treatment eradicated the cancer cells, leaving healthy blood cells alone, and the mice suffered no discernible side effects.

"All cancer cells utilize these two pathways, and they have a strong avidity for these nucleotides to synthesize their DNA or repair it," Nathanson said. "Thus, we believe that this treatment strategy might be applicable across other hematological malignancies besides leukemia."

"Usually people say that drug discovery and development cannot happen strictly in the academic environment — that discovery should be done in academia, and development done elsewhere, such as in industry," said Radu, who also has an appointment in UCLA's interdepartmental program in biomedical physics. "With this study, we show that everything can be done in the academic environment. We started this project from scratch and, with the help of UCLA scientists from many different disciplines, we have taken the drug through all the steps, and now it's nearly ready for clinical trials."

INFORMATION: Among the study's many UCLA collaborators were Dr. Michael Phelps, Norton Simon Professor and chair of molecular and medical pharmacology; Michael Jung, distinguished professor of chemistry and biochemistry; Harvey Herschman, distinguished professor and vice chair of molecular and medical pharmacology and distinguished research professor of biological chemistry; Kym Faull, professor of psychiatry and biobehavioral sciences; and Dr. Johannes Czernin, professor of medicine and director of the nuclear medicine clinic.

This research was supported by the UCLA Scholars in Oncologic Molecular Imaging program, the Jonsson Comprehensive Cancer Center at UCLA, and the National Cancer Institute of the National Institutes of Health.

UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2013, the Jonsson Cancer Center was named among the top 12 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 14 consecutive years.

For more news, visit the UCLA Newsroom and follow us on Twitter.


ELSE PRESS RELEASES FROM THIS DATE:

Huntington proteins and their nasty 'social network'

2014-02-27
Researchers at the Buck Institute have identified and categorized thousands of protein interactions involving huntingtin, the protein responsible for Huntington's disease (HD). To use an analogy of a human social network, the identified proteins are like "friends" and "friends of friends" of the HD protein. The network provides an invaluable resource for identifying targets to treat the disease and has been used to implicate a particular signaling pathway involved in cell motility. HD is an incurable, fatal, inherited neurological disorder that causes severe degeneration ...

Disney researchers look beyond basketball stats to analyze team movement in getting shots

2014-02-27
Everyone knows a basketball player is more likely to miss a three-point shot if a defender is in his face, but a new automated method for analyzing team formations, created by Disney Research Pittsburgh, shows how players get open for a shot: via defensive role swaps. "To an expert, this makes obvious sense – if a defensive player has to move, the space where they moved from is suddenly open and, if their teammate doesn't cover that space quickly, it creates a potential open shot for the offense," said Patrick Lucey, a Disney researcher who specializes in measuring the ...

Disney Research soccer formations analysis suggests home advantage is result of execution

2014-02-27
An automated analysis by Disney Research Pittsburgh of team formations used during an entire season of professional soccer provides further evidence that visiting teams are less successful than home teams because they play conservatively, not because of a mythical home advantage. The researchers, employing the first automated method for detecting formations, analyzed a whole season of player and ball tracking data compiled by Prozone for a top-tier professional soccer league. They found that teams usually played the same formations for both home and away games, but that ...

Altruistic suicide in organisms helps relatives

Altruistic suicide in organisms helps relatives
2014-02-27
The question of why an individual would actively kill itself has been an evolutionary mystery. Death could hardly provide a fitness advantage to the dying individual. However, a new study has found that in single-celled algae, suicide benefits the organism's relatives. "Death can be altruistic – we showed that before – but now we know that programmed cell death benefits the organism's relatives and not just anybody," says Dr Pierre Durand from the Department of Molecular Medicine and Haematology and the Sydney Brenner Institute for Molecular Bioscience (SBIMB) at Wits ...

After death, twin brains show similar patterns of neuropathologic changes

2014-02-27
Despite widespread use of a single term, Alzheimer's disease is actually a diverse collection of diseases, symptoms and pathological changes. What's happening in the brain often varies widely from patient to patient, and a trigger for one person may be harmless is another. In a unique study, an international team of researchers led by USC psychologist Margaret Gatz compared the brains of twins where one or both died of Alzheimer's disease. They found that many of the twin pairs not only had similar progressions of Alzheimer's disease and dementia prior to death, but they ...

Closest, brightest supernova in decades is also a little weird

Closest, brightest supernova in decades is also a little weird
2014-02-27
A bright supernova discovered only six weeks ago in a nearby galaxy is provoking new questions about the exploding stars that scientists use as their main yardstick for measuring the universe. Called SN 2014J, the glowing supernova was discovered by a professor and his students in the United Kingdom on Jan. 21, about a week after the stellar explosion first became visible as a pinprick of light in its galaxy, M82, 11.4 million light years away. Still visible today through small telescopes in the Big Dipper, it is the brightest supernova seen from Earth since SN1987A, ...

Cushing's syndrome: A genetic basis for cortisol excess

2014-02-27
An international team of researchers led by an endocrinologist at Ludwig-Maximilians-Universitaet (LMU) in Munich has identified genetic mutations that result in uncontrolled synthesis and secretion of the stress hormone cortisol. Cortisol is a hormone that is produced by the adrenal gland in response to stressful events, and modulates a whole spectrum of physiological processes. An international research collaboration has now identified genetic mutations that lead to the production and secretion of cortisol in the absence of an underlying stressor. The discovery emerged ...

Why dark chocolate is good for your heart

2014-02-27
It might seem too good to be true, but dark chocolate is good for you and scientists now know why. Dark chocolate helps restore flexibility to arteries while also preventing white blood cells from sticking to the walls of blood vessels. Both arterial stiffness and white blood cell adhesion are known factors that play a significant role in atherosclerosis. What's more, the scientists also found that increasing the flavanol content of dark chocolate did not change this effect. This discovery was published in the March 2014 issue of The FASEB Journal. "We provide a more ...

System-wide analyses have underestimated the importance of transcription in animals

2014-02-27
Over the last ten years, a number of studies have suggested that, in animal cells, translation and protein turnover play a larger role in determining the different levels at which proteins are expressed than transcription. The major evidence supporting these claims is a weak correlation between system-wide protein and mRNA abundance measurements. A highly cited Nature article by Schwanhausser et al. in 2011 provides the most comprehensive example of such analyses. A new study just published in PeerJ by Li et al., however, questions the conclusions of these papers. This ...

Cancer vaccine could use immune system to fight tumors

2014-02-27
CINCINNATI—Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cancer. These findings, published in the Feb. 27 online edition of the journal Gene Therapy, build on previously reported research and could lead to new treatments for cancer. Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for ...

LAST 30 PRESS RELEASES:

Training to improve memory

Are patients undergoing surgery for early-stage cancer at risk of persistent opioid use?

Black youth, especially Black girls, use mental health services less than their White peers

Canada must protect youth from sports betting advertising

First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial

Higher blood pressure in childhood linked to earlier death from heart disease in adulthood

AI helped older adults report accurate blood pressure readings at home

High blood pressure in childhood and premature cardiovascular disease mortality

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy

FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC

CheckMate 77T: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC

Study validates AI lung cancer risk model Sybil in predominantly Black population at urban safety-net hospital

New medication lowered hard-to-control high blood pressure in people with chronic kidney disease

Innovative oncolytic virus and immunotherapy combinations pave the way for advanced cancer treatment

New insights into energy metabolism and immune dynamics could transform head and neck cancer treatment

Pennington Biomedical’s Dr. Steven Heymsfield named LSU Boyd Professor – LSU’s highest faculty honor

Study prompts new theory of human-machine communication

New method calculates rate of gene expression to understand cell fate

Researchers quantify rate of essential evolutionary process in the ocean

Innovation Crossroads companies join forces, awarded U.S. Air Force contract

Using new blood biomarkers, USC researchers find Alzheimer’s disease trial eligibility differs among various populations

Pioneering advances in in vivo CAR T cell production

Natural medicines target tumor vascular microenvironment to inhibit cancer growth

[Press-News.org] Experimental treatment developed at UCLA eradicates acute leukemia in mice